SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-077862
Filing Date
2022-03-17
Accepted
2022-03-17 08:04:32
Documents
14
Period of Report
2022-03-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d275684d8k.htm   iXBRL 8-K 25062
2 EX-99.1 d275684dex991.htm EX-99.1 25771
6 GRAPHIC g275684g0317084425356.jpg GRAPHIC 4760
  Complete submission text file 0001193125-22-077862.txt   189910

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eigr-20220317.xsd EX-101.SCH 2860
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigr-20220317_lab.xml EX-101.LAB 18758
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigr-20220317_pre.xml EX-101.PRE 11713
8 EXTRACTED XBRL INSTANCE DOCUMENT d275684d8k_htm.xml XML 3565
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 22746825
SIC: 2836 Biological Products, (No Diagnostic Substances)